Themis Bioscience Archives

Best in Biotech 28 Dec 2020

A Year to Remember: The Biggest European Biotech News in 2020

The Covid-19 pandemic caused huge disruption for European biotech in 2020, but the industry pulled through. Let’s look back at some of the top moments in the last 12 months. After the many drug approvals, startup foundations, and venture capital highs we saw in 2019, it looked like 2020 was going to be a comfortable […]

December 28, 2020 - 12 minutesmins - By Jonathan Smith

News and Trends 28 May 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

The US-based big pharma MSD has entered the race to be the first to develop an effective vaccine for Covid-19 by acquiring Austrian biotech Themis Bioscience and its vaccine technology for an undisclosed amount. MSD has been a bit slower than some of its contemporaries to announce its plans regarding a potential treatment or vaccine […]

May 28, 2020 - 3 minutesmins - By Helen Albert

News and Trends 20 Mar 2020

Themis and Institut Pasteur Join Coronavirus Vaccine Hunt

The Austrian biotech Themis — specializing in vaccines for infectious and insect-borne diseases — has jumped on the coronavirus vaccine bandwagon along with the Institut Pasteur and other international partners. The collaboration will be led by the Parisian Institut Pasteur, whose vaccine technology — in this case modifying a measles virus vector to carry coronavirus […]

March 20, 2020 - 3 minutesmins - By Jonathan Smith

Themis Biosciences fundraising chikungunya vaccine

News and Trends 18 Sep 2019

Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine

Vienna-based Themis Biosciences has raised €40M in a Series D round to fund a phase III trial that could lead to the approval of the world’s first vaccine for chikungunya infection. The round, one of the largest seen in Austrian biotech so far, was co-led by two new investors, Farallon Capital and Hadean Ventures. […]

September 18, 2019 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Aug 2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide research funding and make an equity investment in Themis Bioscience. In addition, Themis will be eligible to receive up to €200M in milestones, in addition to […]

August 22, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 4 Jun 2019

Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine

The market is in sight for the first potential vaccine for the chikungunya virus, as the company Themis Bioscience will receive up to €18.7M ($21M) in non-dilutive funding to finance the vaccine’s phase III development. The money will cover most of the costs of the phase III trial, which Themis expects to begin later this […]

June 4, 2019 - 2 minutesmins - By Jonathan Smith

Interview 6 May 2019

2019 Will Be a “Year of Realism” for Biotech Investments

Biotech investors regularly jump on new crazes, including the microbiome and CRISPR-Cas9 gene editing. At BIO-Europe Spring 2019, Regina Hodits, Managing Partner at German VC firm Wellington Partners Life Sciences, spoke to us about the firm’s realistic approach to biotech investment. Biotechnology is an industry with high risks and high rewards. Before a medical biotech […]

May 6, 2019 - 6 minutesmins - By Jonathan Smith

chikungunya virus mosquito Themis bioscience

News and Trends 6 Nov 2018

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

The mosquito-borne chikungunya virus may one day have a vaccine, as an Austrian biotech’s lead candidate gets positive results in Phase II. Themis Bioscience measured the blood levels of antibodies against the company’s vaccine in 263 healthy volunteers. Four weeks after injections of its lead candidate vaccine, the participants had produced antibodies to protect themselves […]

November 6, 2018 - 2 minutesmins - By Jonathan Smith

News and Trends 5 Sep 2017

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

UPDATE (05/09/2017): Innovate UK has granted Themis £3M (€3.3M) to push its Chikungunya Vaccine towards Phase III. Originally Published 06/06/2017 Themis Bioscience will test its vaccine candidate against Chikungunya fever in a new Phase I/II trial sponsored by the NIH. Based in Vienna, Themis Bioscience develops new vaccine candidates for emerging diseases like Zika and Chikungunya with its virus […]

September 5, 2017 - 3 minutesmins - By Melanie De Almeida

In Depth 25 Jul 2017

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Tropical diseases are often neglected until an outbreak causes worldwide panic. Here’s how European biotech is preparing for the next one. “What we really need is a very fast and cheap way to develop vaccines,” biotech godfather Greg Winter told me earlier this year. Such precautionary measures may well be on our minds as Europe […]

July 25, 2017 - 6 minutesmins - By Evelyn Warner

vienna biotech valneva sanochemia aop pharma

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Classical music, the Danube, Schnitzel, and apple strüdel – a typical combination of Vienna. The city has also been at the top of rankings for quality of life, innovation, and popular host for conferences. But what about Biotech? Once one of the most influential cities in Europe, Vienna might now be somewhat under the radar […]

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 2 Sep 2016

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

From Switzerland, we depart once again, this time for Vienna. This week, we are visiting Themis Bioscience, our Biotech of the Week (and also stopping for schnitzel). City: Vienna, Austria Founded: 2009 Employees: 4 Financial Data: €10M Total Raised (as of 12/2015) CEO: Erich Tauber Mission: Themis Bioscience targets emerging diseases, like Zika and Chikungunya, and aims to develop […]

September 2, 2016 - 1 minutemin - By Evelyn Warner

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Themis Bioscience

A Year to Remember: The Biggest European Biotech News in 2020

MSD Enters Covid-19 Vaccine Race by Acquiring Themis Bioscience

Themis and Institut Pasteur Join Coronavirus Vaccine Hunt

Themis Raises €40M for First Phase III Trial of a Chikungunya Vaccine

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Austrian Biotech Raises €19M to Commercialize First Chikungunya Vaccine

2019 Will Be a “Year of Realism” for Biotech Investments

First Potential Vaccine for Chikungunya Virus Flies Through Phase II

UPDATE: Austrian Biotech receives €3.3M boost for its Chikungunya Vaccine

Trouble in Paradise: How Biotech is Fighting Tropical Diseases

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Vienna-based Themis Bioscience frontlines vaccine development against emerging diseases

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!